(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 36.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Zevra Therapeutics's revenue in 2026 is $122,289,000.On average, 11 Wall Street analysts forecast ZVRA's revenue for 2026 to be $9,051,110,511, with the lowest ZVRA revenue forecast at $7,843,980,496, and the highest ZVRA revenue forecast at $10,430,265,421. On average, 11 Wall Street analysts forecast ZVRA's revenue for 2027 to be $13,174,978,771, with the lowest ZVRA revenue forecast at $10,074,392,615, and the highest ZVRA revenue forecast at $19,707,786,704.
In 2028, ZVRA is forecast to generate $18,569,821,337 in revenue, with the lowest revenue forecast at $13,788,002,192 and the highest revenue forecast at $27,466,641,479.